Saeko Mizusawa, Yoshiaki Okada

Slides:



Advertisements
Similar presentations
Nick Curry, MD, MPH Infectious Diseases Prevention Section
Advertisements

Marta José, Instituto Grifols S.A., Barcelona, SPAIN
Replacement of the 1 st Parvovirus B19 DNA International Standard SoGAT XXI, Brussels, 28th-29th May 2009 Sally Baylis.
Development of a Panel for Dengue Virus Maria Rios, PhD CBER/FDA Blood Products Advisory Committee Meeting December 14, 2010.
NIBSC Multiplex Proficiency Panel - A multicentre study
Istituto Superiore di Sanità Laboratory of Immunology External quality assessment for detection by NAT of the six major HCV genotypes M Wirz*, GM Bisso*,
The Sense of Sensitivity I Dr. Matthias Gessner Plasma Control Europe/Plasma Analytics Baxter AG, Vienna.
Yi-Chen Yang, Drug Biology Division Bureau of Food and Drug Analysis Department of Health, Taiwan Collaborative study for establishment of the first national.
Paris, May 2004SoGAT XVII SoGAT and the Development of Standards Harvey Holmes Division of Retrovirology NIBSC, UK.
Karen Cristiano Biologicals Unit, CRIVIB Calibration against the WHO Standards of National Reference Preparations for detection of blood viruses by NAT:
Linearity Panels HIV RNA, HCV RNA, HBV DNA, and CMV DNA
XVIII SoGAT Washington 24 May 2005 SoGAT and HIV NAT Standards - 2 nd International Standard for HIV-1 RNA Harvey Holmes*, Clare Davis* and Alan Heath**
PROFICIENCY TESTING OF IN-HOUSE NAT ASSAYS USED FOR BLOOD SCREENING XXI SoGAT International Working Group Meeting on the Standardization of NAT for the.
Generic Automated Sample Preparation for Commercial NAT Assays
ICBS Master Panels for Kit Evaluation: HCV, HBV, and HIV ( Howard A. Fields, Ph.D. Susan Diaz, MPH Division of Viral Hepatitis Centers.
Pooled Source Plasma NAT for HIV-1 An Update from the Bayer HIV-1 IND Study Barbara Masecar Bayer Corporation Raleigh, NC Blood Products Advisory Committee.
BioLife Plasma Services Experience with HBV NAT Testing
HIV, HCV, and HBV NAT Controls Formulation, Stability and Performance Mark Manak BBI Diagnostics, Inc. A Division of SeraCare Life Sciences, Inc. SoGAT.
FDA’s Current Considerations of Parvovirus B19 Nucleic Acid Testing (NAT) Mei-ying W. Yu, PhD Division of Hematology CBER/FDA Extraordinary SoGAT Meeting.
Hepatitis E Virus – Progress in Standardization of NAT-Based Assays Blood Products Advisory Committee Rockville, 20 th September 2012 Sally.
Update on the Replacement of the HCV RNA International Standard Sally Baylis & Alan Heath, NIBSC SoGAT XX, Warsaw June 2007.
SOGAT Validation of HCV-RNA detection in small test pools on cadaveric samples Marco Koppelman #, Theo Cuypers #, Mirjam de Waal #, Maarten.
CE MARKING OF IVDDs - the NIBSC perspective Morag Ferguson Division of Virology.
EQASs for Blood Borne Virus Genomes and BSE Prions from Cattle Brain and INSTAND Reference Materials H.-P. Grunert 1,2, K.-O. Habermehl 1,2, V. Lindig.
Establishment of the 1st WHO International Standard for Detection of Antibodies to Hepatitis B Virus Core Antigen (anti-HBc) SoGAT XXI 29 May 2009 Dr.
Standardisation of P. falciparum HBV, HCV and NAT Sally Baylis, NIBSC SoGAT XVIII.
Stability of HCV, HIV-1 and HBV nucleic acids in plasma samples stored at different temperatures Marta José, Rodrigo Gajardo and Juan I. Jorquera Instituto.
Yi-Chen Yang, Yu-Hsuan Chen, Show-Lan Chiu, Hwei-Fang Cheng Drug Biology Division, Bureau of Food and Drug Analysis Department of Health, Taiwan, ROC National.
Sensitivity of NAT blood screening assays in performance evaluation and proficiency programs Harry van Drimmelen, Nico Lelie, (VQC-Sanquin) and the principal.
NAT Detection of Blood Borne Viral Markers in Tissues from Cadaver Donors John Saldanha 1 and David Padley 2 1 Canadian Blood Services, Ottawa, Canada.
SoGAT XVII/Paris, 2004 Proficiency Testing of In-House Developed HIV-1 NAT for Blood Screening Michael Chudy, Paul-Ehrlich-Institut Division of Virology,
B19 inactivation by heat treatment with epithelial cell lines Yoshiaki Okada Kiyoko Umemori Kazunari Yamaguchi National Institute of Infectious Disease.
1 Preparation of Standard Paneled Plasma for HBV, HCV, and HIV-1 in Japan Hisao Yugi Japanese Red Cross Central Blood Center Study Group of the Ministry.
Development of Standard Reagents for WNV NAT M. Rios, A. Grinev, K. Sirnivasan, O. Wood, S. Daniel, I. Hewlett CBER/FDA.
SoGAT, Berne 2006BTS SRC Berne Ltd. Evaluation of the Procleix TIGRIS System at the Blood Transfusion Service Berne Ltd. Dr. Martin Stolz.
History of ILC Involvement in NAT Standardization 1998: Inter-Organization Discussion for the Establishment of Standard Reference Material for Nucleic.
Blood Products & related Biologicals: SoGAT, 28 May 09 1 |1 | Dr Ana Padilla, Blood Products & related Biologicals Essential Medicines and Pharmaceutical.
Update on the P. falciparum Standard & Replacement of the HBV & HCV International Standards Sally Baylis, NIBSC SoGAT XIX.
NUCLEIC ACID AMPLIFICATION TECHNOLOGY HCV-RNA / HBV-DNA / HIV-RNA testing blood and blood components for transfusion Italian External Quality Assessment.
Elisa Moretti Process and Analytical Development KEDRION S.p.A SoGAT XVI Paul Ehrlich Institut - Langen, Germany 3 rd July 2003 Automated Extraction for.
Preparation of HBV DNA reference standards and the experience of HBV NAT in Taiwan Dr. Hwei-Fang Cheng Department of Health, Taiwan.
Serology - anti-HCV. anti-HIV, HBsAg NAT - HCV RNA - since 2000
An Overall View of Standardization May 26, 2004 Indira Hewlett, Ph.D. CBER/FDA.
DRK-Blutspendedienst West  nPrecipitation steps (PEG), centrifugation and careful resuspension of the invisible pelleted viral particles precede efficient.
An Internet-based application fostering a global collaboration for External Quality Assessment Schemes for Nucleic Acid Testing Thu-Anh Pham 1, Dimech.
DRK-BSD NSTOB & West 19th SoGAT Meeting, 14/15 June 2006, Bern Experience with Roche´s COBAS AmpliPrep/COBAS TaqMan96 automated PCR system in two large.
February 24, 2016 | 1 Paul Strengers MD, FFPM Sanquin Blood Supply Amsterdam The Netherlands Risk assessment schemes: Impact of.
SoGAT May 2005 Are conversion factors to international units assay related? Marco Koppelman, Henk Reesink, Nico Lelie, Theo Cuypers.
Informational Presentation: WHO Biological Standards Summary of January 29-30, 2007 WHO Meeting with WHO Collaborating Centres for Biological Standards.
Progress on Study to Validate Synthetic Materials for Use as Calibrators and References SoGAT XIX Bern, 14 June 2006 Roberta M. Madej Roche Molecular Diagnostics.
HBV DNA Quantification: Results from the UK NEQAS Proficiency Panel
GRIFOLS PLASMA: genotype 2 vB19 sample
Harvey Holmes, Clare Morris and Neil Berry Division of Retrovirology
Results of Recent EQA Panels for Blood Borne Viruses
Tom Øystein Jonassen, Mona Holberg-Petersen, Einar S. Berg
Preparation of plasmids containing HBV-full genome of genotype A to H and trial of HBV inactivation method Yoshiaki Okada Kiyoko Umemori Kazunari.
Longitudinal Quality Assurance of HIV Nucleic Acid Testing in Blood Screening D Jardine, S Best, EM Dax (National Serology Reference Laboratory, Australia)
Roche Molecular Diagnostics
Update on CBER HIV-1 Subtype panel
Evaluation of Candidate Standard XX (97/650)
K.H. Buchheit, A. Daas, C.M. Nübling, J.M. Spieser 3 July 2003
Feasibility of Synthetic Materials as Primary Standards
Italian EQA study for HCV RNA, HIV RNA and HBV DNA G. M. Bisso, K
Viral Safety of Blood Products in Taiwan
1st International Standard for HIV-1 RNA NIBSC Code 97/656
SoGAT Meeting, Berne, 14 June 2006 M. Nübling (PEI, Germany)
Volume 136, Issue 7, Pages (June 2009)
Evaluation of the Abbott Investigational Use Only RealTime HIV-1 Assay and Comparison to the Roche Amplicor HIV-1 Monitor Test, Version 1.5  Michael T.
SoGAT meeting XXI May (2009), Brussels, Belgium
ANALYTICAL CONTROL SYSTEM AS A MEASURE TO ENSURE INFECTIOUS SAFETY OF HUMAN PLASMA FOR FRACTIONATION A.L. Poptsov FSBI “ROSPLASMA” RMSPC of FMBA of RUSSIA.
Presentation transcript:

Establishment of National Standards for NAT Blood Viruses and NAT Proficiency Study Program in Japan Saeko Mizusawa, Yoshiaki Okada National Institute of Infectious Diseases, Japan SoGAT XX In Warsaw, Poland 12-13 June 2007

Study Design for National NAT Standards <Preparation of the Candidate: JRC> A candidate plasma was diluted in cryosupernatant, and stored at –80℃. <Organizer & Participants> NAT Working Group (Chaired by Dr Teruhide Yamaguchi ) Industries for Plasma Derivatives/ JRC/Proficient Labs/NIID < Assay > End-point assay 1st assay: 10-fold dilutions to determine endpoint 2nd –5th assay: 7 half-log dilutions around the endpoint <Potency of the Candidate > Calibrated against WHO International Standards Subcommittee on Safety for Plasma-Derived Products Working Group on the Establishment of National Standard for Nucleic Acid Technology Assay <Preparation of the Candidate> 2 Candidate Source Plasma (>10 6 IU/mL) The selected plasma was diluted to 105IU per mL,-80C   <Assay for Determination of the Potency > End-point assay Five independent assay on different days Five independent assays on different days 1st assay: 10-fold dilution to determine endpoint 2nd –5th assay: 7 half-log dilution around the endpoint Candidate (fresh vial ) WHO IS (reconstitute & distribute in aliquots, stored at –80C) Diluted in plasma <Estimate of the Potency for the Candidate>

Summary of Assays Used for HCV-NAT by the Participants in the Study Table1. Assays used in the collaborative study. a) R&D:Smi-test EX-R&D Amplicor: Amplicor HCV virsion 1 (Roche) QIAamp:QIAamp DNA Blood Mini Kit (QIAGEN) b) Eq. Vol. Amplified : the equivalent volume of sample that was amplified in an assay

Potency of HCV-122 Calibrated against WHO IS for HCV-RNA (96/790) Overall (a) = the overall mean potency calculated from the all laboratories. Overall (b) = the overall mean potency calculated from the data excluding laboratories 1 and 2. Overall (a) = the overall mean potency calculated from the all laboratories Overall (b) = the overall mean potency calculated from the data excluding laboratories 1 and 2.

Potency of HCV-122 Calibrated against WHO IS for HCV-RNA (96/790) Mean 0.01 (-0.204 - 0.201) Anti-log 1.02 (0.979 – 1.588)

Potency of HBV-129 Calibrated against the WHO IS for HBV-DNA (97/746) 3 4 5-1 5-2 6 7 2 -3 -2 -1 Lab. Code No. Log Rerative Potency to IS 97/746 Mean -0.352 (-0.539 - -0.165) Anti-log 0.444 ( 0.289 - 0.684) Relative Potency against WHO IS Potency for HBV-DNA (97/746) ( IU/mL) Log -0.352 ( -0.539 - -0.165) 10 5.65 Anti-log 0.444 ( -0.288 - -0.683) 4.4x10 5

Potency of HIV-00047 Calibrated against the WHO IS for HIV-DNA (97/656) 1.8 temes 10 to the fifth

National Standards for NAT, Japan International standard HCV (genotype) 1.0x105 ( 1b ) ( 1 ) HBV 4.4x105 ( C ) 1.0x106 ( A ) HIV-1 1.4x105 ( B ) IU/mL Each vial of a National Standard contains 0.5ml of positive plasma diluted incryosupernatant and should be stored at –80℃.

NAT Proficiency Program in Japan National Standard for NAT 1999 HCV 2002 HBV 2002 HIV Guideline for industry on NAT 2004 HCV, HBV, HIV detection limit: at least 100IU/mL NAT Control Surveillance 2006 HBV 2007 HCV 2007 HIV

HBV-NAT Control Surveillance 2006 Panel: 3 independent assays National Standard for HBV-NAT (Genotype C) 10000、3000、1000、300、100、30、10 IU/mL & HBV Negative Plasma Laboratories of Industries : Location No. of Industries Laboratories Japan 4 6 USA 2 EU 1 Total 7 10

Results of HBV-NAT Control Surveillance 36 assays =3 assays x 12 assay systems % of Positive results

Summary National Standard for NAT 1999 HCV 2002 HBV 2002 HIV HBV-NAT for Blood Products used in Japan Fulfills Sensitivity Required in Japan NAT Guideline

Collaboration with: Department of Bacteriology II, , NIID Yoshinobu Horiuchi Department of Blood and Safety Research, NIID Mizuochi Toshiaki Kazunari Yamaguchi Working Group on Establishment of the National Standards for Nucleic Acid Technology Assay Working Group on NAT Control Surveillance